Results 161 to 170 of about 17,175,483 (375)

Prospects for effective treatment of AL amyloidosis? [PDF]

open access: bronze, 2000
Neil Iggo   +2 more
openalex   +1 more source

Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR‐CM

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) often experience delayed diagnosis, which may detrimentally impact clinical outcomes. This study aimed to assess the frequency of use of planar scintigraphy with and without single‐photon emission computed tomography (SPECT) in patients with hypertrophic cardiomyopathy (HCM ...
Pablo Garcia‐Pavia   +11 more
wiley   +1 more source

Púrpura. Manifestação de Amiloidose Sistémica Primária [PDF]

open access: yes, 2009
Primary Systemic Amyloidosis (AL) is the most frequent form of systemic amyloidosis and its morbilility is associated with immunoglobulin light chains deposition in vital organs. The mucocutaneous manifestations occur in about 30-40% of the cases and are
Apetato, M   +4 more
core  

The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Proposed algorithm to screen for transthyretin cardiac amyloidosis (ATTR‐CA). AL‐CA, immunoglobulin light‐chain cardiac amyloidosis; AMYLI, AMYLoidosis Index; AUC, area under the curve; IWT, increased wall thickness; LVEF, left ventricular ejection fraction; PYP, pyrophosphate.
Giovanni Battista Bonfioli   +11 more
wiley   +1 more source

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source

Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage

open access: yesEuropean Journal of Heart Failure, EarlyView.
Long‐term efficacy of tafamidis in patients with ATTR‐CM in ATTR‐ACT and its LTE by NAC stage at ATTR‐ACT baseline. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR‐CM, transthyretin amyloid cardiomyopathy; NAC, National Amyloidosis Centre.
Thibaud Damy   +4 more
wiley   +1 more source

Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience [PDF]

open access: yes, 2018
Primary systemic amyloidosis (AL amyloidosis) continues to have a very poor prognosis. Most therapeutic strategies remain unsatisfactory. Conventional chemotherapy is known to offer at best only moderate efficacy.
Cairoli, Anne   +6 more
core  

Atrial cardiomyopathy

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala   +1 more
wiley   +1 more source

Sex‐based differences in heart failure management and outcomes: Insights from the French‐DataHF cohort

open access: yesEuropean Journal of Heart Failure, EarlyView.
Sex differences in heart failure (HF) management and outcomes in the French‐DataHF cohort. CI, confidence interval; HFH, heart failure hospitalization; HR, hazard ratio; IPW, inverse probability weighting; KM, Kaplan–Meier; LD, loop diuretic; RAS, renin–angiotensin system; RASi, renin–angiotensin system inhibitor.
Guillaume Baudry   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy